Skip to content

Home
Product
Team
News
Career
Contact

Home News SEALS Clinical Trial: 1st Patient Enrrolled

News

SEALS Clinical Trial: 1st Patient Enrrolled

15 November, 2024

Axoltis 
60 avenue Rockefeller, 69008 Lyon, France

© 2026 Axoltis. All rights reserved. Disclaimer : NX210c is a drug candidate currently in a Phase 2 clinical trial for ALS and is not yet approved for commercialization.

Legal Notice